Anti-CD3 monoclonal antibody - BTG/Millennium

Drug Profile

Anti-CD3 monoclonal antibody - BTG/Millennium

Latest Information Update: 13 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG; University of Oxford
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 16 Jul 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
  • 16 Jul 2001 Preclinical development for Type-1 diabetes mellitus in United Kingdom (Unknown route)
  • 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top